sickle cell disease

University of MinnesotaFeb 10 2026 A new breakthrough study led by researchers at the University of Minnesota Twin Cities could explain why patients with the same genetic sickle cell mutation experience different levels of pain, organ damage and response to treatment. The study published in Science Advances, shows that the severity of sickle cell disease is […]

by American Society of Hematology edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Credit: Pixabay/CC0 Public Domain Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger than 12. Researchers say the therapy’s potential to offer a cure at an

by American Society of Hematology edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Credit: Pixabay/CC0 Public Domain A study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as manufacturers and medical centers prepare to meet growing demand for gene therapies in the coming years.

by Columbia University Irving Medical Center edited by Robert Egan, reviewed by Andrew Zinin Normal blood cells next to a sickle-blood cell, colored scanning electron microscope image. Credit: Wikipedia/Illustration from Anatomy & Physiology A novel intervention aimed at helping adolescents with sickle cell disease maintain hydroxyurea treatment plans shows promising results at improving their quality of life, a

by Mass General Brigham edited by Stephanie Baum, reviewed by Andrew Zinin Complement pathway schema and hemoglobin (Hb) concentrations in patients during acute chest syndrome (ACS) and at baseline. (A) Schema of complement pathway with highlighted activation proteins analyzed in this study. (B) Hb concentrations from 27 patients during ACS (Acute) and 4 to 8 weeks after hospitalization